Bioassay of XXXX for possible carcinogenicity.

@entity8 @entity137 @entity53303 @entity19 @entity5 @entity4336 @entity957 @entity35 @entity420
A bioassay for possible carcinogenicity of technical-grade @entity53303 ( @entity53303 ) was conducted using Osborne-Mendel @entity35 and B6C3F1 @entity19 . @entity53303 in @entity4336 oil was administered by gavage 5 days a week, at either of two dosages, to groups of 50 male and 50 female animals of each species. Initial dosage levels for the chronic bioassay were selected on the basis of a preliminary subchronic @entity137 test. Subsequent dosage adjustments were made during the course of the chronic bioassay. The time-weighted average dosages of @entity53303 in the chronic study were 29 mg/kg/day for the high dose @entity35 of both sexes, and 15 mg/kg/day for the low dose @entity35 of both sexes. The time-weighted average concentrations for the high dose male and female @entity19 were 219 and 209 mg/kg/day, respectively. The time-weighted average concentrations for the low dose male and female @entity19 were 114 and 110 mg/kg day, respectively. For each species, 20 animals of each sex were placed on test as vehicle controls. These animals were intubated with @entity4336 oil at the same time that dosed animals were intubated with @entity53303 mixtures. Twenty animals of each sex were placed on test as untreated controls for each species. These animals received no gavage treatments. @entity53303 was administered to the high dose male and high dose female @entity35 for 64 weeks prior to sacrifice, and to the low dose female @entity35 for 73 weeks prior to sacrifice. The low dose male @entity35 were treated for 78 weeks followed by an additional 5 weeks of observation. The high dose male and female @entity19 were treated for 47 weeks prior to sacrifice; the low dose male @entity19 were treated for 59 or 60 weeks prior to sacrifice, and the low dose female @entity19 were treated for 60 weeks prior to sacrifice. In @entity35 and @entity19 of both sexes, statistically significant incidences of @entity957 of the forestomach occurred in each dosed group and a significant positive association existed between dosage level and @entity5 incidence. The incidences of @entity420 of the mammary gland were statistically significant in female @entity35 when the treated groups were compared to the controls. @entity8 was also observed at elevated incidences in all of the treated @entity35 and @entity19 when compared to their respective untreated or vehicle control groups. Under the conditions of this study, @entity53303 is a stomach carcinogen in @entity35 and @entity19 of both sexes and is carcinogenic to the mammary gland in female @entity35 .
